[vc_row type=”vc_default” full_width_row=”true” bg_type=”bg_color” bg_override=”full” bg_color_value=”#f4f4f4″ css=”.vc_custom_1491338631580{margin-top: -70px !important;}”][vc_column][vc_custom_heading text=”PARTNER OSR” font_container=”tag:h1|text_align:left|color:%23232323″ use_theme_fonts=”yes”][vc_custom_heading text=”P.I. LUCIA LOPALCO” font_container=”tag:h2|text_align:left|color:%23606060″ use_theme_fonts=”yes”][vc_custom_heading text=”OSPEDALE SAN RAFFAELE” font_container=”tag:h4|text_align:left|color:%238e8e8e” use_theme_fonts=”yes”][/vc_column][/vc_row][vc_row][vc_column width=”1/6″][vc_single_image image=”142″ img_size=”medium” onclick=”custom_link” img_link_target=”_blank” image_hovers=”false” link=”http://www.hsr.it/”][/vc_column][vc_column width=”2/3″][vc_column_text]

Ospedale San Raffaele (OSR) comprises both clinical and research activities, conducted by a highly specialized and qualified hospital with 1,357 beds and a research institute with around 1,600 basic, clinical and translational scientists. The premises also host the Vita-Salute San Raffaele University, which comprises the faculties of medicine, psychology and philosophy.

Lucia Lopalco is currently the Head of the Immunobiology of HIV Lab of the OSR in Milan. Dr Lopalco studies the mechanisms underlying dysfunction of immune system under alterations of self repertoire associated to increased susceptibility to infection or development of inflammation or cancer. She is responsible of a Work Package within HEPAMUT project. Her lab will be fully involved in Identification of HCC specific neo-antigen and development of monoclonal antibodies against conformational HCC epitopes.

[/vc_column_text][/vc_column][vc_column width=”1/6″][vc_single_image image=”267″ img_size=”full” alignment=”center” image_hovers=”false”][/vc_column][/vc_row][vc_row][vc_column]


1) Venuti et al., ERK-1 Based Pathway as a New Selective Mechanism To Modulate CCR5 with Natural Antibodies. J Immunol 2015;195:3045-57.

2) Pastori C et al., Induction of HIV blocking anti-CCR5 IgA in Peyer’s Patches without histopathological alterations. J Virol. 2014; 88:3623-35.

3) Brombin et al., A nonparametric procedure for defining a new humoral immunologic profile in a pilot study on HIV infected patients. PloS One 2013; 8(3): e58768.

4) Tudor T et al., The immunoglobulin CH1 constant region of the anti-HIV-1 broadly neutralizing 2F5 human antibody contributes extensively to epitope specificity, affinity and antiviral activities. PNAS 2012: 109:12680-12685.

5) Burastero SE et al., Broad-Spectrum Inhibition of HIV-1 by a Monoclonal Antibody Directed against a gp120-Induced Epitope of CD4. PLoS One 2011; 6(7):e22081.